SAN DIEGO, June 01, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will present at the investor conferences listed below. Management will also participate in one-on-one investor meetings.
Jefferies Healthcare Conference (June 7 – 9, 2023)
Location: Marriott Marquis, New York, NY
Format: Presentation
Date and Time: Wednesday, June 7, 1:00-1:25 PM EDT
Webcast: https://wsw.com/webcast/jeff281/eras/1846130
Goldman Sachs Global Healthcare Conference (June 12 – 15, 2023)
Location: Waldorf Astoria Monarch Beach Resort & Club, Dana Point, CA
Format: Fireside Chat
Date and Time: Monday, June 12, 3:20-3:55 PM PDT
Webcast: https://cc.webcasts.com/gold006
An archived replay of the events will be available for 30 days following the webcast at Erasca.com/events.
About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled what we believe to be the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Contact:
Joyce Allaire
LifeSci Advisors, LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$2.63 |
Daily Change: | 0.04 1.54 |
Daily Volume: | 2,924,133 |
Market Cap: | US$455.940M |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB